Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS
Content archived on 2024-06-18

Novel MS-based strategies to Discover and Evaluate Cancer Biomarkers in urine: Application to Diagnosis of Bladder Cancer

Objective

In clinical studies, proteomics and transcriptomics allow the comparison of samples from different patients and hold special promise for the discovery of novel biomarkers and the development of “personalized medicine” approaches. Yet, translating recent discoveries into daily medical practice takes time and despite intensified researchers’ interest and investments, the rate of introduction of novel biomarkers in clinical practice is extremely disappointing. The main aim of DECanBio is to implement a strategy for protein biomarker discovery and validation relying on the use of “state of the art” mass spectrometry instrumentation for quantitative analysis of proteins. For the first time, the potential of MRM-Mass Spectrometry (MRM-MS) will be tested in the scope of a large scale validation protocol of cancer protein biomarkers. This analysis will be performed in parallel to the application of miniaturized high-throughput ELISA tests for protein quantification. DECanBio strategy will be applied to issues related to bladder cancer. Specifically, a restricted number of urinary protein biomarkers enabling the detection of recurrences during the monitoring period of patients treated for bladder tumour will be validated. The work will be performed in priority for the follow-up of low-grade superficial bladder tumours (Ta stage), which, after initial resection (without BCG therapy), are likely to evolve towards remission, recurrence, or progression to a high-grade tumor. The MRM and ELISA tests developed herein aim at the high-throughput quantification of these markers in urine. Collectively, the project has the ambition to settle a whole experimental pipe-line, from the search for new bladder cancer biomarker candidates, to their thorough evaluation and validation in clinical environment. We anticipate that the tools and knowledge that will be developed here will greatly facilitate translational studies for other diseases as well.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

FP7-HEALTH-2007-A
See other projects for this call

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

CP-FP - Small or medium-scale focused research project

Coordinator

COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES
EU contribution
€ 615 656,33
Address
RUE LEBLANC 25
75015 PARIS 15
France

See on map

Region
Ile-de-France Ile-de-France Paris
Activity type
Research Organisations
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

No data

Participants (8)

My booklet 0 0